Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 + anlotinib + nab-paclitaxel first-line phase II study in advanced triple-negative breast cancer
ChiCTR2100054980Phase 2Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Apr 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab, anlotinib and paclitaxel in triple-negative breast cancer (TNBC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Objective response rate. Started Apr 2022; status: recruiting.
02
Drugs
penpulimabanlotinibpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2100054980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054980.